Overcoming therapeutic resistance in glioblastoma: Moving beyond the sole targeting of the glioma cells

Poole, Alisha; Lun, Xueqing; Robbins, Stephen M.; Senger, Donna L.

doi:10.1016/b978-0-12-821310-0.00009-7

Cited by 1 publication

(1 citation statement)

References 204 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…FDA-approved checkpoint inhibitors at various stages of clinical trials are currently at different stages of output (Vaddepally et al 2020 ). In spite of initial success in lymphoma and melanoma, the results on breast and prostate cancer is not very impressive, the major barrier responsible for limited response in breast and prostate tumor is immune-suppression in TME (Petty and Yang 2017 ), with tumor-associated macrophage playing dominant role or providing resistance to immunotherapy at TME(Poole et al 2021 ). Further TAM also promotes carcinogenesis via secreting cytokines, growth factors that facilitate migration, invasion and metastasis (Chen et al 2019 ).…”

Section: Extrinsic Pathwaymentioning

confidence: 99%

Nanomedicines: intervention in inflammatory pathways of cancer

Anwar

Naqvi

Shams³

et al. 2023

Inflammopharmacol

View full text Add to dashboard Cite

Inflammation is a complex defense process that maintains tissue homeostasis. However, this complex cascade, if lasts long, may contribute to pathogenesis of several diseases. Chronic inflammation has been exhaustively studied in the last few decades, for its contribution in development and progression of cancer. The intrinsic limitations of conventional anti-inflammatory and anti-cancer therapies triggered the development of nanomedicines for more effective and safer therapies. Targeting inflammation and tumor cells by nanoparticles, encapsulated with active therapeutic agents, offers a promising outcome with patient survival. Considerable technological success has been achieved in this field through exploitation of tumor microenvironment, and recognition of molecules overexpressed on endothelial cells or macrophages, through enhanced vascular permeability, or by rendering biomimetic approach to nanoparticles. This review focusses on the inflammatory pathways in progression of a tumor, and advancement in nanotechnologies targeting these pathways. We also aim to identify the gaps that hinder the successful clinical translation of nanotherapeutics with further clinical studies that will allow oncologist to precisely identify the patients who may be benefited from nanotherapy at time when promotion or progression of tumor initiates. It is postulated that the nanomedicines, in near future, will shift the paradigm of cancer treatment and improve patient survival. Graphical abstract

show abstract